全球生长激素障碍治疗市场 – 行业趋势及 2030 年预测

生长激素障碍治疗市场分析和规模

根据美国儿科学会的数据，人类生长激素缺乏症是一种罕见疾病，在美国，每 3,000 到 10,000 名儿童中就有不到 1 名患有此病。当今市场上人类生长激素药物随处可​​见，这提高了人们对其健康益处的认识，从而进一步增加了多家制造公司的收入。对此类药物的需求正在增加生长激素疾病的发病率。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球生长激素障碍治疗市场的增长率。在上述预测期内，全球生长激素障碍治疗市场的预期复合年增长率约为 9.11%。2022 年市场价值为 55.3885 亿美元，到 2030 年将增长至 111.2592 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

生长激素障碍治疗市场范围和细分

Market Definition

Growth hormone disorder is a rare type of condition that is typically characterized by inadequate secretion of growth hormone (GH) from the anterior pituitary gland. This kind of hormones can be present since birth and cause serious genetic mutation or structural defects in the brain. The growth hormone disorders can be acquired in the later years due to the presence of severe infection, trauma among others. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy.

Global Growth Hormone Disorder Treatment Market Dynamics

Drivers

• Increasing Trend of urban lifestyle

Urban lifestyles and deteriorating food habits are projected to increase the demand for human growth hormone drugs and diverse treatment facilities. There has been an increase in stress and sleeplessness because of the hectic life patterns of the citizens working in cities. This is causing huge hormonal imbalance in the body. Medication growth hormones help in such situations and thus are becoming more popular among youngsters and old people around the world.

• Increase in Growth Disorders

There has been a continuing increase in public understanding regarding the use of synthetic growth hormone therapy. The expanding industrial research for the causes of growth disorders, along with an improving incidence of diagnosis, led to an increase in market growth. Many growth-related issues such as adult growth hormone deficiency, pediatric growth hormone deficit, idiopathic low stature, and hereditary illnesses such as Turner syndrome and Prader-Willi syndrome are contributing enough to boost the market size. Globally, 1 in 3800 children suffers from a growth hormone deficit. Turner syndrome affects about 1 in every 2000 females, and Prader-Willi syndrome affects 1 in every 30,000 persons. Thus, it boosts the market growth.

Opportunities

• Increased Clinical Studies and Related Activities

Robust product pipeline and wide R&D activities for the development of novel growth hormone therapies are projected to be the major factors pushing the market growth. For instance, in September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, that is specified for the treatment of pediatric growth hormone deficiency. In addition to this, in May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, that is indicated for pediatric growth hormone deficiency.

• Growing Government Initiatives

The various initiatives taken by numerous government and private organizations to spread awareness about growth hormone deficiencies and human growth hormone treatment are projected to drive the market. Each year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), which is a U.S.-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day to spread awareness about the diagnosis and treatment of growth hormone disorders to initiate fast recovery among humans, particularly children.

 Restraints/Challenges

• Risk of Complications

The growth hormone disorder treatment market has a high risk of complications. Complications such as the possible side effects of growth hormone therapy which include knee, hip, or other joint pain; allergic reactions, such as rash, swelling, or hives, and an increase in blood sugar levels are witnessed post the therapy. Thus, it hampers the market growth.

• High Cost

The huge expenditure associated with these drugs hamper the market growth. The growth hormone disorder drugs cost high and thus sometimes becomes unaffordable for the lower economic groups.

This global growth hormone disorder treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global growth hormone disorder treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Growth Hormone Disorder Treatment Market          

COVID-19 几乎对每个商业部门都产生了重大影响，反过来也阻碍了制药行业的发展。在 2020 年 3 月开始的疫情年中，人类生长激素注射量大幅下降。COVID-19 对全球生长激素障碍治疗市场产生了负面影响。在后疫情时代，由于患者容易感染病毒，对人类生长激素治疗和药物的需求不断增加。此外，《前沿》杂志发表的一份报告指出，患有普拉德-威利综合征的患者在感染后可能会出现迟发性症状，这积极增加了美国及其他地区对人类生长激素治疗的需求。

最新动态：

• 2021年2月，辉瑞和OPKO health Inc.宣布，欧洲药品管理局已批准Somatrogon用于治疗青少年生长激素缺乏症患者。
• 2021年8月，Ascendis Pharma 的 SKYTROFA 注射剂获得了 FDA 批准。该产品在全球市场上市后，该公司预计将获得巨额营业额。

全球生长激素障碍治疗市场范围

全球生长激素障碍治疗市场根据类型、疾病、分销渠道和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 获得性 GHD
• 先天性生长激素缺乏症
• 特发性生长激素缺乏症
• 其他的

疾病

• 小于胎龄儿 (SGA)
• 身材矮小
• 特发性身材矮小
• 特纳综合征
• 努南综合征
• 普拉德-威利综合征
• 拉伦综合征
• 巨人症和肢端肥大症
• 其他的

最终用户

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

生长激素障碍治疗市场区域分析/见解

对全球生长激素紊乱治疗市场进行了分析，并按类型、紊乱、分销渠道和最终用户提供了市场规模洞察和趋势。

全球生长激素障碍治疗市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于该地区对生长激素的研发活动增加和医疗保健基础设施完善，北美在整个预测期内一直见证着全球生长激素紊乱治疗市场的积极增长。

由于技术进步和慢性病和代谢疾病发病率不断上升，亚太地区占据了市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球生长激素障碍治疗市场份额分析

全球生长激素障碍治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球生长激素障碍治疗市场的关注有关

全球生长激素紊乱治疗市场的主要参与者包括：

• 梯瓦制药工业有限公司 (以色列)
• Amneal Pharmaceutical Inc（美国）
• Mayne Pharma Group Limited（澳大利亚）
• 默克集团（德国）
• 赛诺菲（法国）
• 太阳制药工业有限公司 (印度)
• 诺华公司（瑞士）
• F. Hoffmann-La Roche Ltd（瑞士）
• 雅培（美国）
• PT. Daewoong 制药公司 (韩国)
• 基因泰克公司（美国）
• Bausch Health Companies Inc.（加拿大）
• 礼来（美国）
• 益普生制药（法国）
• Ferring BV（瑞士）

SKU-56109